# Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

> **NCT03166735** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 114 (actual)

## Conditions studied

- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** BI 1467335
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03166735
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-06
- **Primary completion:** 2019-06-14
- **Final completion:** 2019-06-14
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2020-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03166735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03166735, "Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03166735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*